Remdesivir investigational trials in COVID-19: a critical reappraisal

New Microbes New Infect. 2020 Jun 7:100707. doi: 10.1016/j.nmni.2020.100707. Online ahead of print.

Abstract

During outbreak of emerging disease, the most important aim is to discover an effective drug to save life. Consequently, a lot of effort are generally made by the industry to promote clinical trials with new drugs. Here we review evidence of the 8 most recent reports including 3 randomized controlled trials on the clinical efficacy of remdesivir in treating COVID-19 patient. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention.

Publication types

  • Editorial